FCRLA and renal cell carcinoma: The ESTIMATE score, which combines the immune and stromal scores, suggests that RCC patients with higher FCRLA expression have worse prognosis but a higher abundance of immune infiltrating cells, which might make them more responsive to immunotherapy.